EUVIMEDEUVIMED entdecken
Crossref

Theranostic Folate-Targeted Doxorubicin-Loaded MIL-88A@CuFe 2 O 4 Nanohybrids, a pH-Sensitive, Core–Shell, Mesoporous Drug Delivery Platform with Dual-Modal T1–T2MRI and Optical Imaging Contrast Properties: An In Vitro and In Vivo Cancer Study

Motahareh Rezvan iD, Amirhosein Kefayat iD, Mohammadmahdi Doostmohammadi iD, Fatemeh Molaabasi iD, Gholamhossein Riazi iD, Mahmoud Reza Aghamaali, Babak Mikaeeli Kangarshahi, Ramin Sarrami Forooshani

ACS Applied Bio Materials · 2026

DOI: 10.1021/acsabm.5c01914 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2026. Verfasst von Motahareh Rezvan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Nanotechnology Group, Department of Interdisciplinary Technologies, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran 15…. Hauptthemen laut MEDLINE: Doxorubicin, Folic Acid, Theranostic Nanomedicine, Optical Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 122 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinFolic AcidTheranostic NanomedicineOptical ImagingBiocompatible MaterialsAntibiotics, AntineoplasticDrug Delivery SystemsAnimalsCopperHydrogen-Ion ConcentrationHumansMagnetic Resonance ImagingMiceFerric CompoundsPorosityParticle SizeMaterials TestingFemaleDrug Screening Assays, AntitumorCell Line, TumorCell SurvivalCell ProliferationContrast MediaNanoparticlesFerrous Compounds

Stichwörter der Autor:innen

Metal−Organic frameworksT1-T2 contrast agentcopper ferrite nanoparticlesmultimodal imagingtargeted theranostics

Substanzen

DoxorubicinFolic AcidCopperFerric CompoundsBiocompatible MaterialsCuFe2O4Antibiotics, AntineoplasticContrast MediaFerrous Compounds

Autor:innen und Institutionen

  • Medical Nanotechnology Group, Department of Interdisciplinary Technologies, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran 1517964311, Iran.
  • Department of Biology, Faculty of Sciences, University of Guilan, Rasht 4199613776, Iran.
  • Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH8 9YL, U.K.
  • Department of Gastroenterology, Western General Hospital, Edinburgh EH4 2XU, U.K.
  • Department of Biochemistry, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran 1417614411, Iran.
  • Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Academic Center for Education, Culture and Research (ACECR), Motamed Cancer Institute, Tehran 1517964311, Iran.

ORCID-Profile: Motahareh Rezvan, Amirhosein Kefayat, Mohammadmahdi Doostmohammadi, Fatemeh Molaabasi, Gholamhossein Riazi

Zitieren

APA

Rezvan, M., Kefayat, A., Doostmohammadi, M., Molaabasi, F., Riazi, G., Aghamaali, M. R., Mikaeeli Kangarshahi, B., & Sarrami Forooshani, R. (2026). Theranostic Folate-Targeted Doxorubicin-Loaded MIL-88A@CuFe 2 O 4 Nanohybrids, a pH-Sensitive, Core–Shell, Mesoporous Drug Delivery Platform with Dual-Modal T1–T2MRI and Optical Imaging Contrast Properties: An In Vitro and In Vivo Cancer Study. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.5c01914

Vancouver

Rezvan M, Kefayat A, Doostmohammadi M, Molaabasi F, Riazi G, Aghamaali MR, et al. Theranostic Folate-Targeted Doxorubicin-Loaded MIL-88A@CuFe 2 O 4 Nanohybrids, a pH-Sensitive, Core–Shell, Mesoporous Drug Delivery Platform with Dual-Modal T1–T2MRI and Optical Imaging Contrast Properties: An In Vitro and In Vivo Cancer Study. ACS Applied Bio Materials. 2026. doi:10.1021/acsabm.5c01914

BibTeX
@article{Rezvan2026,
  author = {Rezvan, Motahareh and Kefayat, Amirhosein and Doostmohammadi, Mohammadmahdi and Molaabasi, Fatemeh and Riazi, Gholamhossein and Aghamaali, Mahmoud Reza and Mikaeeli Kangarshahi, Babak and Sarrami Forooshani, Ramin},
  title = {Theranostic Folate-Targeted Doxorubicin-Loaded MIL-88A@CuFe 2 O 4 Nanohybrids, a pH-Sensitive, Core–Shell, Mesoporous Drug Delivery Platform with Dual-Modal T1–T2MRI and Optical Imaging Contrast Properties: An In Vitro and In Vivo Cancer Study},
  journal = {ACS Applied Bio Materials},
  year = {2026},
  doi = {10.1021/acsabm.5c01914}
}
Kostenlos starten →